Table 1. Immunohistochemical analysis of FOXM1 and DLX1 on an ovarian cancer tissue array (OVC1021, Pantomics, Inc.).
| Characteristics | Total |
DLX1 expression (fold change) |
P-value | |
|---|---|---|---|---|
| ⩽Eightfold | >Eightfold | |||
| All cases | 97 | 47 (48.5%) | 50 (51.5%) | |
| Stage | ||||
| Early (1) | 48 | 25 (52.1%) | 23 (47.9%) | |
| Late (2 and 3) | 49 | 22 (44.9%) | 27 (55.1%) | 0.545 |
| Grade | ||||
| Low (1 and 2) | 50 | 36 (72.0%) | 14 (28.0%) | |
| High (3) | 46 | 10 (21.7%) | 36 (78.3%) | <0.001* |
| Metastasis | ||||
| No | 73 | 36 (49.3%) | 37 (50.7%) | |
| Yes | 24 | 11 (45.8%) | 13 (54.2%) | 0.817 |
| FOXM1 (2xfold) | ||||
| Underexpression | 58 | 36 (62.1%) | 22 (37.9%) | 0.002* |
| Overexpression | 39 | 11 (28.2%) | 28 (71.8%) | |
Higher expression of DLX1 was found in higher tumor grading (*P<0.001, Fisher's exact test). No significant difference was found in tumor stages and metastatic status. DLX1 was positively correlated with FOXM1 expression in immunohistochemical analysis (*P=0.002, Fisher's exact test).